JPRN-UMIN000008252已完成未知
RCT PhaseII trial of Paclitaxel (P) and Carboplatin (C) plus continuous Gemcitabine (G) versus Gemcitabine (G) and Carboplatin (C) plus continuous Gemcitabine in untreated non-small cell lung cancer (NSCLC) - RCT PhaseII trial of Paclitaxel (P) and Carboplatin (C) plus continuous Gemcitabine (G) versus Gemcitabine (G) and Carboplatin (C) plus continuous Gemcitabine in untreated non-small cell lung cancer (NSCLC)
Respiratory, Osaka University Hospital0 个研究点目标入组 100 人开始时间: 2012年6月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Having the bleeding tendency which is clear in clinic 2)An agreement is not obtained for support therapy such as transfusion etc 3)Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor 4) History of severe heart disease (uncontrollable arrythmia, uncontrollable angina pectoris, congestive heart failue, etc within 6 months) 5)Patients with jaundice 6)Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray 7)Patiens has pleural effusion, pericardial effusion and ascites to need treatment for 8)Acute inflammatory disease 9)Uncontrollable diabetes mellitus and hypertenson 10)Patients with mental disorders seems to be in need of treatment or during treatment with psychotropic drugs 11)Sub-cases considered severe intestinal obstruction, or intestinal obstruction clinically 12)Patients with complications considered serious to interfere with the performance of treatment 13)Patients with suspected infection 14)Patients with a history of hypersensitivity to (such as cyclosporine injection)-containing preparations (Kuremohoru EL ®) polyoxyethylene castor oil 15)Patients with disease-free interval is less than five years without treatment and even in patients with cancer or metachronous duplication of activity 16)Patients with brain metastases with the clinical symptoms 17) Patients who underwent radiation therapy to the lesions can be evaluated 18) The patient has drug allergies 19)Serious Patients with) will (possibly during pregnancy and pregnancy or lactating 20) principal investigator cases that are deemed inappropriate
研究者
相似试验
已完成
2 期
Phase II Study of Paclitaxel and Carboplatin plus Bevacizumab in StageIIIA-N2, IIIB, IV patients with Nonsquamous Non-Small-Cell Lung Cancerchemotherapy-na&iumlve StageIIIA-N2, IIIB, IV patients with nonsquamous non-small-cell lung cancerJPRN-UMIN000006809Akita University Graduate School of Medicine31
进行中（未招募）
不适用
A phase II trial of carboplatin and paclitaxel compared with carboplatin or gemcitabine paclitaxel induction followed by carboplatin/paclitaxel/gemcitabine in patients with suboptimally resected stage III or IV ovarian carcinoma - NDEUCTR2006-000126-31-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
招募中
2 期
A Phase II study of Paclitaxel plus Carboplatin plus Bevacizumab that introduces concept of Clinical PD in recurrent or advanced non-squamous non-small cell lung cancer.recurrent or advanced non-squamous non-small-cell and lung cancer.JPRN-UMIN000005328Dept. of Respiratory Medicine, Osaka University Hospital45
进行中（未招募）
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10075566Term: Triple negative breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-004651-23-FRInstitut Jules Bordet180
招募中
1 期
A Phase I/II Study of Paclitaxel plus Carboplatin and Durvalumab (MEDI4736) with or without Oleclumab (MEDI9447) for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple-Negative Breast CancerPreviously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC)MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10075566Term: Triple negative breast cancer Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10006198Term: Breast cancer recurrent Class: 100000004864CTIS2024-511850-34-00Institut Jules Bordet209